29.21
+0.34(+1.18%)
Currency In USD
| Previous Close | 28.87 |
| Open | 28.94 |
| Day High | 30.9 |
| Day Low | 27.3 |
| 52-Week High | 39.9 |
| 52-Week Low | 3.6 |
| Volume | 269,272 |
| Average Volume | 234,807 |
| Market Cap | 203.18M |
| PE | -1.88 |
| EPS | -15.54 |
| Moving Average 50 Days | 19.13 |
| Moving Average 200 Days | 12.06 |
| Change | 0.34 |
If you invested $1000 in Scilex Holding Company (SCLX) since IPO date, it would be worth $84.73 as of September 29, 2025 at a share price of $29.21. Whereas If you bought $1000 worth of Scilex Holding Company (SCLX) shares 3 years ago, it would be worth $80.79 as of September 29, 2025 at a share price of $29.21.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Scilex Holding Company Announces Closing of Previously Announced Initial Tranche Investment in Datavault AI
GlobeNewswire Inc.
Sep 26, 2025 7:57 PM GMT
PALO ALTO, Calif. , Sept. 26, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management produ
Scilex Holding Company Announces $150 Million Strategic Bitcoin Investment in Datavault AI
GlobeNewswire Inc.
Sep 25, 2025 7:45 PM GMT
PALO ALTO, Calif., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management produc
Scilex Announces Closing of Previously Announced Non-Dilutive Value Enhancing Transaction with an Institutional Investor for the Exchange of $200 Million of Common Stock of Semnur Pharmaceuticals, Inc. Held by Scilex Holding Company for $200 Million in Bitcoin
GlobeNewswire Inc.
Sep 25, 2025 10:00 AM GMT
PALO ALTO, Calif., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management produc